Bioprocess engineering firm OmniBRx announces a Series A equity fundraising from SIDBI Venture Capital Limited for 30 crore inr.
Commenting on the occasion, Ravindra Patel, founder and CEO of OmniBRx Biotechnologies said “We are thankful to the team at SVCL for believing in our vision and backing us on our expansion plans”. He further added that “Scalable and Efficient bioprocessing technologies, specifically the Single-use bioreactor platforms are in high demand worldwide for the production of vaccines and other biologicals. Innovation based technology solutions from OmniBRx has potential to meet these exponentially growing market demands of biologics and vaccines
The CellBRx Single- use Bioreactors from OmniBRx is the world’s largest and most efficient vaccine manufacturing platform for large scale vaccines and viral vector Production. OmniBRx is also the creator of world’s first integrated seed train development platforms in close-loop sequentially programmed bioreactor systems” Ravindra added.
With infusion of series-A funds, OmniBRx is all set to expand their business in the overseas market. The company would also invest in adding to its capacity and build best in class manufacturing facilities to augment its production capabilities and meet growing market demands.
Sajit Kumar. Sr. VP at SIDBI Venture Capital Limited quoted “We are happy to partner with OmniBRx. We believe that their focus and deep domain knowledge will help them to penetrate the global markets. This is our third investment out of “Ubharte Sitaare Fund”, fund for MSME’s focused on scaling up in the export markets. Wishing them all the best“.
